(d) -CO-$NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are -H and C_1-C_4 alkyl, and where R_{3-2} and R_{3-3} are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

R_{3-2} and R_{3-3} should be R_{N-2} and R_{N-3}, respectively.

It should read:

(d) -CO-$NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are -H and C_1-C_4 alkyl, and where R_{N-2} and R_{N-3} are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

The R groups being discussed are R_N and not R_3. Please correct this typographical error.

CONCLUSION

Accordingly, it is believed that claims 24-25 are now in condition for allowance, early notice of which would be appreciated.

If any outstanding issues remain, Examiner is invited to telephone the undersigned to discuss the same. No fee is believed to be due for the submission of this response. Should any fees be required, please charge such fees or credit overpayment to Deposit Account No. 21-0718.

Respectfully submitted,

Mary Hosley

Date: 16 September 2004

Mary Hosley, Attorney
Registration No. 48,324

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (269) 833-0975 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316

Specification

Please replace formula (XII) in the specification starting on page 1, line 26 and ending on page 4, line 11, as follows (previous amendments are incorporated):

Disclosed is a 9-arylsulfone of the formula (XII)



where R_3 is:

(1) -H,

(2) C_1-C_4 alkyl,

(3) C_0-C_4 alkyl-ϕ where the -ϕ substituent is optionally substituted with 1 or 2

(a) -F, -Cl, -Br, -I,

(b) -O-$R_{3\text{-}1}$ where $R_{3\text{-}1}$ is:

-H,

C_1-C_4 alkyl,

-ϕ,

(c) -CF_3,

(d) -CO-$NR_{3\text{-}2}R_{3\text{-}3}$ where $R_{3\text{-}2}$ and $R_{3\text{-}3}$ are -H and C_1-C_4 alkyl, and where $R_{3\text{-}2}$ and $R_{3\text{-}3}$ are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

(e) -NH-SO_2-$R_{3\text{-}4}$ where $R_{3\text{-}4}$ is -H and C_1-C_4 alkyl,

(f) -$NR_{3\text{-}2}R_{3\text{-}3}$ where $R_{3\text{-}2}$ and $R_{3\text{-}3}$ are as defined above,

(g) -$NR_{3\text{-}4}$-CO-$R_{3\text{-}4}$ where $R_{3\text{-}4}$ is as defined above,

(h) -SO_2-$NR_{3\text{-}2}R_{3\text{-}3}$ where $R_{3\text{-}2}$ and $R_{3\text{-}3}$ are as defined above,

(i) -C≡N,

(j) -NO_2,

where R_N is:

(1) -H,

(2) C_1-C_4 alkyl,

(3) C_0-C_4 alkyl-ϕ where the -ϕ substituent is optionally substituted with 1 or 2

(a) -F, -Cl, -Br, -I,

(b) -O-R_{N-1} where R_{N-1} is

-H,

C_1-C_4 alkyl,

-ϕ,

(c) -CF_3,

(d) -CO-$NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are -H and C_1-C_4 alkyl, and where $R_{[[3]]N-2}$ and $R_{[[3]]N-3}$ are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

(e) -NH-SO_2-R_{N-4} where R_{N-4} is -H and C_1-C_4 alkyl,

(f) –$NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are as defined above,

(g) –NR_{N-4}-CO-R_{N-4} where R_{N-4} is as defined above,

(h) -SO_2-$NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are as defined above,

(i) -C≡N,

(j) -NO_2,

where R_X is:

(1) -H

(2) -F, -Cl, -Br, -I,

(3) -O-R_{X-1} where R_{X-1} is:

-H,

C_1-C_4 alkyl,

-ϕ,

(4) -CF_3,

(5) -CO-$NR_{X-2}R_{X-3}$ where R_{X-2} and R_{X-3} are -H and C_1-C_4 alkyl, and where R_{X-2} and R_{X-3} are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

(6) -NH-SO_2-R_{X-4} where R_{X-4} is -H and C_1-C_4 alkyl,

(7) –$NR_{X-2}R_{X-3}$ where R_{X-2} and R_{X-3} are as defined above,

(8) –NR_{X-4}-CO-R_{X-4} where R_{X-4} is as defined above,

(9) -SO_2-$NR_{X-2}R_{X-3}$ where R_{X-2} and R_{X-3} are as defined above,

(10) -C≡N,

(11) -NO_2;

where R_9 is:

(1) -H,

(2) –F, -Cl,

(3) C_1-C_4 alkyl,

(4) C_1-C_3 alkoxy,

(5) $-CF_3$,

(6) C_0-C_4 alkyl-ϕ where the -ϕ substituent is optionally substituted with 1 or 2

(a) -F, -Cl, -Br, -I,

(b) -O-R_{9-1} where R_{9-1} is:

-H,

C_1-C_4 alkyl,

-ϕ,

(c) $-CF_3$,

(d) -CO-$NR_{9-2}R_{9-3}$ where R_{9-2} and R_{9-3} are -H and C_1-C_4 alkyl, and where R_{9-2} and R_{9-3} are taken with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl,

(e) -NH-SO_2-R_{9-4} where R_{9-4} is -H and C_1-C_4 alkyl,

(f) –$NR_{9-2}R_{9-3}$ where R_{9-2} and R_{9-3} are as defined above,

(g) –NR_{9-4}-CO-R_{9-4} where R_{9-4} is as defined above,

(h) -SO_2-$NR_{9-2}R_{9-3}$ where R_{9-2} and R_{9-3} are as defined above,

(i) -C≡N,

(j) $-NO_2$

(7) –OR_{9-1} where R_{9-1} is as defined above,

(8) –CO-$NR_{9-2}R_{9-3}$ where R_{9-2} and R_{9-3} are as defined above,

(9) –$NR_{9-2}R_{9-3}$ where R_{9-2} and R_{9-3} are as defined above,

(10) –NH-SO_2-R_{9-4} where R_{9-4} is as defined above,

(11) –NH-CO_2-R_{9-2} where R_{9-2} is as defined above,

and pharmaceutically acceptable salts thereof.